{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:10:00Z","timestamp":1790633400412,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) results from clonal expansion of immunoglobulin secreting, heavy chain class-switched, terminally differentiated B-lymphocytes (plasma cells), resulting in radiologic or biochemical evidence of end-organ damage. Though neurological manifestations (peripheral neuropathies, spinal radiculopathies, cranial nerve palsies, and metabolic encephalopathies) can occur during the disease course, direct central nervous system (CNS) infiltration by malignant plasma cells (CNS-MM) is very rare (~1%) and has a dismal prognosis (survival of &lt;6 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>Clinico-laboratory profile and outcome of CNS-MM patients diagnosed and treated at a tertiary cancer care hospital were retrospectively analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>On scrutinizing 500 consecutive myeloma case records, 4 patients with CNS-MM were identified. All these patients were diagnosed during myeloma relapse, and all had deceased within 1 week and 12 months of developing CNS infiltration. Our experience with CNS-MM patients is similar to the experiences documented across major world literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our manuscript reinforces that CNS-MM should be considered in any myeloma patient presenting with unexplainable CNS manifestations. As there are no prospective studies to recommend optimal treatment strategies, CNS-MM still remains a dismal complication of myeloma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijc.ijc_560_20","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T12:00:25Z","timestamp":1688990425000},"page":"416-422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Central nervous system involvement in multiple myeloma: Experience from a tertiary cancer center and review of literature"],"prefix":"10.4103","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-9861","authenticated-orcid":false,"given":"Kavita","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Oncopathology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-886X","authenticated-orcid":false,"given":"Karthik","family":"Bommannan","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-6591","authenticated-orcid":false,"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-274X","authenticated-orcid":false,"given":"Jhansi Rani","family":"Arumugam","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-8001","authenticated-orcid":false,"given":"Tenali Gnana","family":"Sagar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-7107","authenticated-orcid":false,"given":"Shirley","family":"Sundersingh","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Cancer Institute (W.I.A.), Adyar, Chennai \u2013 600020, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"R1-20251122","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"Blad\u00e9","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"R2-20251122","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.beha.2005.01.024","article-title":"Neurological aspects of multiple myeloma and related disorders","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-20251122","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.2002.03401.x","article-title":"Myeloma of the central nervous system:Association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations","volume":"117","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"R4-20251122","doi-asserted-by":"crossref","first-page":"3970169","DOI":"10.1155\/2018\/3970169","article-title":"Multiple myeloma of the central nervous system:13 cases and review of the literature","volume":"2018","author":"Varga","year":"2018","journal-title":"J Oncol"},{"key":"R5-20251122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2013.11.004","article-title":"Patterns of central nervous system involvement in relapsed and refractory multiple myeloma","volume":"14","author":"Abdallah","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R6-20251122","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma:A multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"key":"R7-20251122","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clml.2016.08.010","article-title":"Myelomatous involvement of the central nervous system","volume":"16","author":"Paludo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R8-20251122","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/archneur.61.9.1423","article-title":"Multiple myeloma invasion of the central nervous system","volume":"61","author":"Schluterman","year":"2004","journal-title":"Arch Neurol"},{"key":"R9-20251122","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma:Long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"R10-20251122","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents:A retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"R11-20251122","first-page":"30","article-title":"Multiple myeloma and central nervous system involvement:Experience of a Brazilian center","volume":"40","author":"Dias","year":"2018","journal-title":"Rev Bras Hematol Hemoter"},{"key":"R12-20251122","first-page":"745","article-title":"Central nervous system multiple myeloma:A different cytogenetic profile?","volume":"164","author":"Chang","year":"2014","journal-title":"Am J Hematol"},{"key":"R13-20251122","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO;2-3","article-title":"Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature","volume":"62","author":"Petersen","year":"1999","journal-title":"Am J Hematol"},{"key":"R14-20251122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central nervous system myelomatosis:Review of the literature","volume":"80","author":"Nieuwenhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"R15-20251122","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2141.2005.05493.x","article-title":"The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system","volume":"129","author":"Chang","year":"2005","journal-title":"Br J Haematol"},{"key":"R16-20251122","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","article-title":"Multiple myeloma involving central nervous system:High frequency of chromosome 17p13. 1 (p53) deletions","volume":"127","author":"Chang","year":"2004","journal-title":"Br J Haematol"},{"key":"R17-20251122","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"R18-20251122","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ccr3.1451","article-title":"Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab","volume":"6","author":"Elhassadi","year":"2018","journal-title":"Clin Case Rep"},{"key":"R19-20251122","doi-asserted-by":"crossref","first-page":"omy038","DOI":"10.1093\/omcr\/omy038","article-title":"Successful eradication of leptomeningeal plasma cell disease","volume":"2018","author":"Bruserud","year":"2018","journal-title":"Oxf Med Case Reports"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_560_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:15Z","timestamp":1787067435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_560_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_560_20","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"2020-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}